Table 2.
Treatment method and outcome of the 17 patients who received intraperitoneal PTX in an adjuvant setting
| Patient No. | PTX IP, mg/m2 | PTX IV, mg/m2 | Cycle of PTX, n/weeks | Period of PTX, months | S-1, mg/day | Period of S-1, months | Outcome | Recurrence site |
|---|---|---|---|---|---|---|---|---|
| 1 | 20 | – | 1/2 | 6 | 40 | 6 | 7-year survival | – |
| 2 | 20 | – | 2/3 | 10 | 50 | 2 | 7-year survival | – |
| 3 | 20 | – | 1/2 | 5 | 50 | 6 | 7-year survival | – |
| 4 | 60 | – | 1/2 | 6 | – | 6 | 7-year survival | – |
| 5 | 60 | – | 1/2 | 36 | 40 | 36 | 7-year survival | – |
| 6 | 20 | – | 2/3 | 4 | 80 | 12 | 7-year survival | – |
| 7 | 60 | – | 2/3 | 14 | 80 | 14 | 34 months dead | liver |
| 8 | 50 | – | 1/2 | 3 | 40 | 12 | 7-year survival | – |
| 9 | 60 | – | 1/2 | 6 | 40 | 2 | 6-year survival | – |
| 10 | 20 | – | 2/3 | 6 | 80 | 6 | 6-year survival | – |
| 11 | 20 | – | 1/2 | 9 | 40 | 12 | 6-year survival | – |
| 12 | 20 | 50 | 2/3 | 4 | 80 | 6 | 14 months dead | liver |
| 13 | 20 | 50 | 2/3 | 6 | 80 | 12 | 5-year survival | – |
| 14 | 20 | 50 | 2/3 | 4 | 80 | 12 | 5-year survival | peritoneum |
| 15 | 20 | 50 | 2/3 | 24 | 80 | 24 | 5-year survival | – |
| 16 | 20 | 50 | 2/3 | 4 | 80 | 12 | 5-year survival | – |
| 17 | 20 | 50 | 2/3 | 4 | 80 | 6 | 2-year survival | – |
IP = Intraperitoneal; IV = intravenous.